Síndrome Inflamatorio Multi Sistémico Asociado a COVID 19 en Pediatría
Palabras clave:
pediatría, COVID-19, Síndrome Inflamatorio Multi Sistémico
Resumen
Si bien la pandemia global por coronavirus pareció afectar en forma leve a los niños, y así fue reportado en marzo del 2020, por el centro de Control y Prevención (CDC) de China, (epicentro de la pandemia) que describió solo el 1 % del total de la población afectada eran infantes. La transmisión a niños ha sido inicialmente descripta a partir de adultos o contactos cercanos portadores de la infección y alguna evidencia de transmisión de la ruta oro-fecal. El periodo de incubación de la enfermedad en niños es entre 2 y 10 días. Si bien la mayoría de ellos son asintomáticos, u oligosintomáticos, los síntomas más comunes reportados en enfermedad aguda han sido fiebre, tos, rinorrea, conjuntivitis y dolor de cabeza. Diarrea, dolor abdominal también pueden presentarse asociados o no a síntomas respiratarios; esto fue descripto en todas las edades de 0 a 19 años. Sólo en el 0.6% ha sido reportada la ocurrencia de una enfermedad severa.Citas
I. Rúa Figueroa I; Erausquin C. Factores asociados con mortalidad en lWu Z., McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
II. Dong Y., Mo X., Hu Y., et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus disease in China. Pedia-trics. 2020;145(6): e20200702.doi: 10.1542/ peds.2020-0702 32179660 51.
III. . de Masson A., Bouaziz JD, Sulimovic L., et al. Chilblains are a com-mon cutaneous finding during the COVID-19 pandemic: a retros-pective nationwide study from France. Arch Acad Emerg Med. 2020;83(2):667–670.
IV. . Riphagen S., Gomez X., Gonzalez-Martinez C., et al. Hyperin-flammatory shock in children during Covid 19 pandemic. Lancet. 2020;395(10237):1607–1608
V. Koné-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-li-ke disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020 Jun;6(2): e001333. doi: 10.1136/rmdopen-2020-001333
VI. Swan O., Holden K., Tuthe L., et al. Clinical characteristics of chil-dren and young people admitted to hospital with covid-19 in Uni-ted Kingdom: prospective multicentre observational cohort study BMJ 2020 Aug 27;370:m3249. doi: 10.1136/bmj.m3249
VII. Colafrancesco R., Alessandrini C., Conti F., et al. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020 Jul;19(7):102573. doi: 10.1016/j. autrev.2020.102573. Epub 2020 May 5.
VIII. Jamilloux Y., Henry T., Belot A., et al. Should we stimulate or su-ppress immune responses in COVID-19? Cytokine and anti-cyto-kine interventions. Autoimmun Rev 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
IX. Fu Y., Cheng Y., Wu Y. Understanding SARS-CoV-2-Mediated In-flammatory Responses: From Mechanisms to Potential Therapeu-tic Tools. Virologica Sinica 2020; 35:266–271 doi.org/10.1007/s12250-020-00207-4
X. Weisberg S.P., Connors T., Zhu Y., et al. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19 medRxiv 2020 Jul 14; 2020.07.12. 20151068. doi: 10.1101/2020.07.12.20151068.
XI. Noval Rivas M., Porritt R.A., Hongying Cheng M., et al. COVID-19 As-sociated Multisystem Inflammatory Syndrome in Children (MIS-C): a novel disease that mimics Toxic Shock Syndrome. The superan-tigen hypothesis. Journal of Allergy and Clinical Immunology 2020 Oct 16; S0091-6749(20)31414-7. doi: 10.1016/j.jaci.2020.10.008
XII. Henderson L A., Canna S W., Friedman K G., et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 and Hyperin-flammation in Pediatric COVID-19. Version 1. Arthritis Rheumatol. 2020 Jul 23;10.1002/art.41454. doi: 10.1002/art.41454
XIII. Jonat B., Gorelik M., Boneparth A., et al. Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children’s Hospital in New York City: Patient Characteris-tics and an Institutional Protocol for Evaluation, Management, and Follow-Up. Pediatr Crit Care Med. 2020 Sep 29. doi: 10.1097/ PCC.0000000000002598
II. Dong Y., Mo X., Hu Y., et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus disease in China. Pedia-trics. 2020;145(6): e20200702.doi: 10.1542/ peds.2020-0702 32179660 51.
III. . de Masson A., Bouaziz JD, Sulimovic L., et al. Chilblains are a com-mon cutaneous finding during the COVID-19 pandemic: a retros-pective nationwide study from France. Arch Acad Emerg Med. 2020;83(2):667–670.
IV. . Riphagen S., Gomez X., Gonzalez-Martinez C., et al. Hyperin-flammatory shock in children during Covid 19 pandemic. Lancet. 2020;395(10237):1607–1608
V. Koné-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-li-ke disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020 Jun;6(2): e001333. doi: 10.1136/rmdopen-2020-001333
VI. Swan O., Holden K., Tuthe L., et al. Clinical characteristics of chil-dren and young people admitted to hospital with covid-19 in Uni-ted Kingdom: prospective multicentre observational cohort study BMJ 2020 Aug 27;370:m3249. doi: 10.1136/bmj.m3249
VII. Colafrancesco R., Alessandrini C., Conti F., et al. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020 Jul;19(7):102573. doi: 10.1016/j. autrev.2020.102573. Epub 2020 May 5.
VIII. Jamilloux Y., Henry T., Belot A., et al. Should we stimulate or su-ppress immune responses in COVID-19? Cytokine and anti-cyto-kine interventions. Autoimmun Rev 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
IX. Fu Y., Cheng Y., Wu Y. Understanding SARS-CoV-2-Mediated In-flammatory Responses: From Mechanisms to Potential Therapeu-tic Tools. Virologica Sinica 2020; 35:266–271 doi.org/10.1007/s12250-020-00207-4
X. Weisberg S.P., Connors T., Zhu Y., et al. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19 medRxiv 2020 Jul 14; 2020.07.12. 20151068. doi: 10.1101/2020.07.12.20151068.
XI. Noval Rivas M., Porritt R.A., Hongying Cheng M., et al. COVID-19 As-sociated Multisystem Inflammatory Syndrome in Children (MIS-C): a novel disease that mimics Toxic Shock Syndrome. The superan-tigen hypothesis. Journal of Allergy and Clinical Immunology 2020 Oct 16; S0091-6749(20)31414-7. doi: 10.1016/j.jaci.2020.10.008
XII. Henderson L A., Canna S W., Friedman K G., et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 and Hyperin-flammation in Pediatric COVID-19. Version 1. Arthritis Rheumatol. 2020 Jul 23;10.1002/art.41454. doi: 10.1002/art.41454
XIII. Jonat B., Gorelik M., Boneparth A., et al. Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children’s Hospital in New York City: Patient Characteris-tics and an Institutional Protocol for Evaluation, Management, and Follow-Up. Pediatr Crit Care Med. 2020 Sep 29. doi: 10.1097/ PCC.0000000000002598
Publicado
2020-12-01
Cómo citar
1.
Álvarez MB, Espada G. Síndrome Inflamatorio Multi Sistémico Asociado a COVID 19 en Pediatría. Rev. Argent. Reumatol. [Internet]. 1 de diciembre de 2020 [citado 19 de abril de 2024];31(4):20 -24. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/383
Sección
Actualizaciones
Derechos de autor 2021 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
